glp 1 agonist liraglutide activates key brain circuits to trigger weight loss in obesity Liraglutide is a GLP-1 Receptor

This underscores the need for both RWE and RCTs in parallel and reinforces the need to need to run clinical trials that reflect real-world populations, a topic explored in more detail in our blog Obesity trials on trial Some health improvement seen with GLP-1 therapy may be a direct effect of weight loss, rather than unique drug effect as seen by improvements in liver and kidney health 4

The alignment of regulatory frameworks with clinical guidelines further supports the adoption of GLP-1 drugs, indicating a positive trajectory for the market in the coming years

Hagan, Jr., Shaw Judith S., Paula M., Duncan M

PMID: 25277394

PMID: 16406191